Baseline Thymopoietic Function and Post-Transplant Immune Recovery after Adult Cord Blood Transplantation  by Benjamin, Cara L. et al.
Table 2
Transplant Outcomes for MMUD vs MUD Grafts
Outcome Group N 1-yr CI 2-yr CI p-
value
MUD 169 0.72 (0.64-0.79) 0.60 (0.51-0.67) -
8/10 Loci 31 0.57 (0.38-0.73) 0.43 (0.25-0.60) 0.04
OS 9/10 Loci 105 0.71 (0.61-0.79) 0.56 (0.45-0.65)
Single DQB1 18 0.78 (0.51-0.91) 0.72 (0.45-0.87) 0.44
Single C 26 0.68 (0.46-0.83) 0.45 (0.25-0.64) 0.07
Single class 1
or DRB1
87 0.70 (0.59-0.79) 0.522 (0.41-0.63) 0.17
MUD 169 0.65 (0.57-0.72) 0.54 (0.45-0.62) -
8/10 Loci 31 0.47 (0.29-0.64) 0.40 (0.23-0.57) 0.04
DFS 9/10 Loci 105 0.65 (0.55-0.74) 0.50 (0.40-0.60)
Single DQB 18 0.78 (0.51-0.91) 0.72 (0 45-0.87) 0.29
Single C 26 0.56 (0.35-0.73) 0.37 (0.18-0.56) 0.14
Single DQB1 87 0.64 (0.53-0.73) 0.47 (0.36-0.58) 0.42
MUD 169 0.09 (0.04-0.14) 0.13 (0.08-0.19) -
8/10 Loci 31 0.07 (0.01-0.19) 0.13 (0.40-0.28) 0.36
aGvHD
(Gr 2-4)
9/10 Loci 105 0.14 (0.08-0.22) 0.21 (0.14-0.30)
Single DQB1 18 0.17 (0.04-0.37) 0.17 (0.04-0.37) 0.21
Single C 26 0 04 (0.00-0.17) 0.23 (0.09-0.41) 0.62
Single class 1
or DRB1
87 0.14 (0.08-0.22) 0.22 (0.14-0.32) 0.21
MUD 169 0.05 (0.02-0.09) 0.10 (0.05-0.16) -
8/10 Loci 31 0.03 (0.00-0.15) 0.03 (0.00-0.15) 0.14
cGvHD 9/10 Loci 105 0.03 (0.01-0.08) 0.03 (0.01-0.08)
Single DQB1 18 0.06 (0.00-0.25) 0.06 (0.00-0.25) 0.67
Single C 26 0.05 (0.00-0.20) 0.05 (0.00-0.20) 0.41
Single class 1
or DRB1
87 0.03 (0.00-0.08) 0.03 (0.00-0.08) 0.06
*As appropriate, logrank or Gray’s test p-value comparing outcomes for
single DQB1, Single C and Single class 1 or DRB1 to MUD transplants.
Similarly, outcomes were compared across 8/10 loci, 9/10 loci and 10/10 loci
MUD transplants.
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CD34+ selection +/- sRBCr. Conditioning regimens were
ablative and all included ATG. Patients were in remission or
had a low volume of disease. No pharmacologic GvHD pro-
phylaxis was given. For different levels of mismatch, overall
(OS) and disease-free survival (DFS) were compared using
Kaplan-Meier curves and the logrank test. Cumulative inci-
dence functions and Gray’s test compared the incidence of
grade 2-4 aGvHD and cGvHD. Results were compared with
169 TCD HLA matched unrelated donor (MUD) grafts during
the same period.
Results: Table 1 lists demographics. Several subgroups had
limited numbers of patients. Table 2 shows cumulative
incidence (CI) for outcomes, and Figure 1 survival curves to 5
yrs. There was no difference in outcomes for 1 loci MMUD vs.
MUD grafts. There was no statistical difference in outcomes
for a single C vs. any single non C mismatch. Nearly all acute
GVHDwas 2-3, and therewere only 4 limited chronic GVHDs.
OS and DFS were lower for >1 loci MMUD transplants.
Conclusion: These results support the use of TCD MMUD
grafts as alternatives for patients lacking a MUD or ineligible
for a CB graft.198
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Aims:We reported the impact of hemophagocytic syndrome
(HPS) on engraftment failure in cord blood transplantation
(CBT). The aim of this study was to explore pathogenesis
underlying HPS.
Methods: We retrospectively reviewed 351 patients who
underwent single CBT using ﬂudarabine-based regimens
at our institute from January 2002 to July 2011
consecutively.
Results: Median age was 58 years (range, 17-82).Diagnoses
were AML/MDS (n¼209), ALL/ML (n¼103), and others
(n¼36). Tacrolimus plus MMF (TAC+MMF) were used in 196
cases as GVHD prophylaxis, while TAC alone in 155. HPS
developed in 33 patients at a median of 19 days post-CBT.
The cumulative incidence of HPS was 9.4%. Development of
HPS had a negative impact signiﬁcantly on neutrophil
engraftment (33.3% with HPS vs 83.3% without HPS,
p¼<0.01), which resulted in inferior overall survival rate.
Majority of the HPS patients (25/30) showed donor-domi-
nant chimerism at the diagnosis of HPS. Patients with severe
form of pre-engraftment immune reactions (sPIR) showed
signiﬁcantly higher incidence of HPS than those without PIR
(51.9% vs 6.6% p¼<0.01). Patients who received cord blood
unit with higher degree of HLA antigen mismatch in GVH
direction (2 vs 0-1) also showed higher incidence of HPS
(11.5% vs 4.8% p¼<0.04). TAC+MMF decreased the incidence
of sPIR and HPS compared to TAC alone (2.8% vs 15.3%
p¼<0.01 and 4.6% vs 15.5% p¼ <0.01, respectively), which
had a trend toward higher engraftment rate (83.7% vs 72.3%
p¼0.07). In multivariate analysis, GVHD prophylaxis using
TAC alone, lower number of CD34+ cells infused (>0.8x105/kg
vs <0.8x105/kg) and higher degree of HLA antigen mismatch
in GVH direction were signiﬁcantly associated with HPS
development.
Conclusion: HPS was closely associated with engraftment
failure in our CBT cohort. sPIR plays an crucial role of
developing HPS and was possibly controlled by intensiﬁca-
tion of GVHD prophylaxis.IMMUNE RECONSTITUTION
199
Baseline Thymopoietic Function and Post-Transplant
Immune Recovery after Adult Cord Blood Transplantation
Cara L. Benjamin 1, Rima Saliba 2, Elizabeth J. Shpall 3,
Marcos J.G. de Lima 4, Lisa St. John 5, Paul Szabolcs 6,
Richard E. Champlin 7, Krishna V. Komanduri 8. 1 Adult Stem
Cell Transplant Program, Sylvester Cancer Center - University of
Miami, Miami, FL; 2 Department of Stem Cell Transplantation
and Cellular Therapy, University of Texas, MD Anderson Cancer
Center, Houston, TX; 3 Stem Cell Transplantation and Cellular
Therapy, The University of Texas MD Anderson Cancer Center,
Houston, TX; 4 University Hospitals Case Medical Center,
Cleveland, OH; 5 Stem Cell Transplantation and Cellular
Therapy, MD Anderson Cancer Center, Houston, TX; 6 Pediatrics,
Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA;
7 Stem Cell Transplantation & Cellular Therapy, UT MD
Anderson Cancer Center, Houston, TX; 8 Adult Stem Cell
Transplant Program, University of Miami, Miami, FL
We previously published data from a group of 32 heavily










%NK (median) 45 13.3% 17.2% p¼0.035
80 7.0% 11.3% p¼0.0015
%NK/PD-1
(median)
45 0.59% 0.42% ns
80 0.96% 0.37% p¼0.0003
%NK/IFN-g
(median)
45 2.7% 1.2% p¼0.03
80 1.8% 1.2% p¼0.03
%NK Perforin
(median)
45 60.2% 39.2% p¼0.04
80 25.4% 41.8% ns
%NK/Granzyme
(median)
45 91.3% 85.7% p¼0.02
80 89.8% 86.2% p¼0.04
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S145found that their post-transplant immune recovery was
characterized by a failure to recover early thymopoiesis and
impairment of functional T cell recovery, compared to other
recipients of autologous or allogeneic transplants (Koman-
duri et al., Blood, 2007). We now report a more extensive
study of adult CBT recipients in whom thymopoiesis was
prospectively assessed by measuring T cell receptor excision
circles (TRECs) in the peripheral blood. Thymic function was
assessed prior to CBT, and at varying intervals thereafter. A
total of 71 adult CBT recipients were assessed prior to CBT
and also assessed at least once within the ﬁrst 180 days after
CBT. Of these recipients, 44 of 71 had detectable thymopoi-
esis prior to the start of conditioning (62%), while baseline
thymopoiesis was undetectable in others (38%). In CBT re-
cipients with detectable thymopoiesis at baseline, 32% had at
least one sample demonstrating detectable thymopoiesis by
six months post-transplant. In contrast, only 4% of subjects
with a negative baseline had any detectable thymopoiesis by
six months. These results suggest that the recovery of early
thymopoiesis within the ﬁrst six months of CBT in adults
may be dependent on functional thymopoiesis at baseline.
Univariate landmark of a subset of these CBT recipients
(n¼41) stratiﬁed by the recovery of thymopoiesis at six
months after CBT demonstrated that recovery of thymopoi-
esis was positively associated with overall survival (HR¼0.2,
95% conﬁdence interval 0.1-0.7, P¼0.01), and also with
decreased non-relapsed mortality (HR¼0.2, 95% conﬁdence
interval 0.1-0.9, p¼0.04). Larger studies of baseline thymo-
poiesis prior to hematopoietic transplantationwill be helpful
to conﬁrm these ﬁndings and ascertain how and why thy-
mopoiesis is preserved in a subset of patients, and to deter-
mine more precisely the relationship of baseline function
and post-CBT outcomes.
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Cytomegalovirus (CMV) infection represents a major
complication in hematopoietic stem cell transplantation
(HCT). There is accumulating evidence that immune re-
sponses to CMV infection involve the expansion of speciﬁc
subsets of NK cells largely driven by the activating receptor
NKG2C.
Under an IRB approved protocol (COH 09038), we prospec-
tively examined the reconstitution of NK cells post-HCT
(days 21, 30, 45, 80 and 120) with regards to their immu-
nophenotypes and functions. A total of 111 patients are
enrolled (median age: 54, range 19-70) who underwent HCT
from related (n¼49) or unrelated donors (n¼62) after either
fully ablative (n¼36) or reduced-intensity (n¼75) condi-
tioning. Donor (D)/Recipient (R) serostatus was D+/R+ in 69,D-/R+ in 33, and D+/R- in 6 pairs. Acute GVHD grade II-IV was
observed in 49 patients (47%). CMV reactivations were seen
in 26 patients (23.4%) with the median time of reactivation
on day 49, including 2 cases of CMV disease.
CMV reactivationwas signiﬁcantly associated with increased
%NK cells expressing PD-1, IFN-gamma, perforin, and gran-
zyme B (Table 1). More focused analysis on available day 80
samples (n¼75) demonstrated a signiﬁcant increase in NK
cells expressing NKG2C in patients with CMV reactivations
(24.2%, n¼17) compared with no reactivations (13.2%, n¼58,
p¼0.018), consistent with published reports. Among
NKG2C+NKcells, CMV reactivation was associated with
increased granzyme B (85.4% vs. 56.9%, p¼0.003) and Ki67
expression (7.0% vs. 2.9%, p¼0.03).
We further explored NK responses to CMV antigen by co-
culturing PBMC (day 80 samples) and pp65 peptide mix for
24 hours. There was no signiﬁcant change in %NKG2C+NK
cells before and after pp65 stimulation. Interestingly,
NKG2C-NK cells showed a response to pp65 stimulation in
their expression of CD137 (pre: 0.06% vs. post: 0.23%,
p¼0.005) and IFN-gamma (pre: 1.6% vs. post: 2.1%, p¼0.03 in
CMV reactivators), suggesting a potential role of NKG2C-NK
cells in CMV infections.
In summary, our data support that CMV reactivation is
associated with expansion (Ki67) and cytotoxic functions
(perforin, granzyme, IFN-gamma) of NK cells expressing
NKG2C following allogeneic HCT.201
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Poor reconstitution of T cell immunity after umbilical cord
blood transplantation (UCBT) results in susceptibility to viral
infections that require intact T cell immunity. Epstein Barr
